Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives

Current Cancer Drug Targets

Volumn 11, Issue 3, 2011, Pages 239-253

  Chen, D ^a,b   Frezza, M ^a,b   Schmitt, S ^a,b   Kanwar, J ^a,b   Dou, Q P ^a,b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bortezomib; Chemotherapy; Multiple myeloma; Proteasome inhibitors; The ubiquitin proteasome pathway

Indexed keywords

ARSENIC TRIOXIDE; ASCORBIC ACID; BORTEZOMIB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLAVONOID; GREEN TEA EXTRACT; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LENALIDOMIDE; MELPHALAN; MITOXANTRONE; MYRICETIN; PEMETREXED; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL XL; QUERCETIN; SOMATOMEDIN C; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE E3;

ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; APPETITE DISORDER; ARTHRALGIA; ARTICLE; BODY SURFACE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER RELAPSE; CANCER RESISTANCE; CELL INTERACTION; CELL SURVIVAL; CHEMOSENSITIZATION; DIARRHEA; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TOLERANCE; DYSPNEA; EDEMA; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ERYTHROCYTE COUNT; FATIGUE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; IC 50; INFECTION; INSOMNIA; KIDNEY CARCINOMA; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CANCER; OVARY CARCINOMA; PARESTHESIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; RADIOSENSITIZATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TINGLING; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR XENOGRAFT; VOMITING; WEAKNESS;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 79951702955     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911794519752     Document Type: Article

References (163)

1. Adams, J. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 2004, 4, 349-360
2. Ciechanover, A. The ubiquitin-proteasome proteolytic pathway. Cell 1994, 79, 13-21
3. Hochstrasser, M. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr. Opin. Cell Biol. 1995, 7, 215-223
4. Orlowski, R. Z.; Dees, E. C. The role of the ubiquitination- proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res. 2003, 5, 1-7
5. Berenson, J. R.; Yang, H. H.; Sadler, K.; Jarutirasarn, S. G.; Vescio, R. A.; Mapes, R.; Purner, M.; Lee, S. P.; Wilson, J.; Morrison, B.; Adams, J.; Schenkein, D.; Swift, R. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J. Clin. Oncol. 2006, 24, 937-944
6. Kane, R. C.; Farrell, A. T.; Sridhara, R.; Pazdur, R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin. Cancer Res. 2006, 12, 2955-2960
7. Kane, R. C.; Bross, P. F.; Farrell, A. T.; Pazdur, R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003, 8, 508-513
8. Kane, R. C.; Dagher, R.; Farrell, A.; Ko, C. W.; Sridhara, R.; Justice, R.; Pazdur, R. Bortezomib for the treatment of mantle cell lymphoma. Clin. Cancer Res. 2007, 13, 5291-5294
9. Orlowski, R. Z.; Eswara, J. R.; Lafond-Walker, A.; Grever, M. R.; Orlowski, M.; Dang, C. V. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 1998, 58, 4342-4348
10. Adams, J.; Palombella, V. J.; Sausville, E. A.; Johnson, J.; Destree, A.; Lazarus, D. D.; Maas, J.; Pien, C. S.; Prakash, S.; Elliott, P. J. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999, 59, 2615-2622
11. Orlowski, R. Z.; Stinchcombe, T. E.; Mitchell, B. S.; Shea, T. C.; Baldwin, A. S.; Stahl, S.; Adams, J.; Esseltine, D. L.; Elliott, P. J.; Pien, C. S.; Guerciolini, R.; Anderson, J. K.; Depcik-Smith, N. D.; Bhagat, R.; Lehman, M. J.; Novick, S. C.; O'Connor, O. A.; Soignet, S. L. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 2002, 20, 4420-4427
12. Dou, Q. P.; Goldfarb, R. H. Bortezomib (millennium pharmaceuticals). IDrugs 2002, 5, 828-834
13. Fisher, R. I.; Bernstein, S. H.; Kahl, B. S.; Djulbegovic, B.; Robertson, M. J.; de Vos, S.; Epner, E.; Krishnan, A.; Leonard, J. P.; Lonial, S.; Stadtmauer, E. A.; O'Connor, O. A.; Shi, H.; Boral, A. L.; Goy, A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 2006, 24, 4867-4874
14. Papandreou, C. N.; Daliani, D. D.; Nix, D.; Yang, H.; Madden, T.; Wang, X.; Pien, C. S.; Millikan, R. E.; Tu, S. M.; Pagliaro, L.; Kim, J.; Adams, J.; Elliott, P.; Esseltine, D.; Petrusich, A.; Dieringer, P.; Perez, C.; Logothetis, C. J. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol. 2004, 22, 2108-2121
15. Potts, B. C.; Lam, K. S. Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides. Mar. Drugs 2010, 8, 835-880
16. Singh, A. V.; Palladino, M. A.; Lloyd, G. K.; Potts, B. C.; Chauhan, D.; Anderson, K. C. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. Br. J. Haematol. 2010, 149, 550-559
17. Fenical, W.; Jensen, P. R.; Palladino, M. A.; Lam, K. S.; Lloyd, G. K.; Potts, B. C. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg. Med. Chem. 2009, 17, 2175-2180
18. Kuhn, D. J.; Chen, Q.; Voorhees, P. M.; Strader, J. S.; Shenk, K. D.; Sun, C. M.; Demo, S. D.; Bennett, M. K.; van Leeuwen, F. W.; Chanan-Khan, A. A.; Orlowski, R. Z. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin- proteasome pathway, against preclinical models of multiple myeloma. Blood 2007, 110, 3281-3290
19. O'Connor, O. A.; Stewart, A. K.; Vallone, M.; Molineaux, C. J.; Kunkel, L. A.; Gerecitano, J. F.; Orlowski, R. Z. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin. Cancer Res. 2009, 15, 7085-7091
20. Goldberg, A. L. Protein degradation and protection against misfolded or damaged proteins. Nature 2003, 426, 895-899
21. Orlowski, R. Z.; Kuhn, D. J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res. 2008, 14, 1649-1657
22. Ciechanover, A.; Orian, A.; Schwartz, A. L. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 2000, 22, 442-451
23. Ciechanover, A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 1998, 17, 7151-7160
24. Peters, J. M.; Cejka, Z.; Harris, J. R.; Kleinschmidt, J. A.; Baumeister, W. Structural features of the 26 S proteasome complex. J. Mol. Biol. 1993, 234, 932-937
25. Baumeister, W.; Walz, J.; Zuhl, F.; Seemuller, E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 1998, 92, 367-380
26. Groll, M.; Ditzel, L.; Lowe, J.; Stock, D.; Bochtler, M.; Bartunik, H. D.; Huber, R. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997, 386, 463-471
27. Groll, M.; Heinemeyer, W.; Jager, S.; Ullrich, T.; Bochtler, M.; Wolf, D. H.; Huber, R. The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 10976-10983
28. DeMartino, G. N.; Slaughter, C. A. The proteasome, a novel protease regulated by multiple mechanisms. J. Biol. Chem. 1999, 274, 22123-22126
29. Goldberg, A. L.; Cascio, P.; Saric, T.; Rock, K. L. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol. Immunol. 2002, 39, 147-164
30. Coux, O.; Tanaka, K.; Goldberg, A. L. Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. 1996, 65, 801-847
31. Nandi, D.; Tahiliani, P.; Kumar, A.; Chandu, D. The ubiquitin- proteasome system. J. Biosci. 2006, 31, 137-155
32. Hershko, A.; Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67, 425-479
33. Adams, J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 2003, 29 Suppl 1, 3-9
34. Hoyt, M. A.; Coffino, P. Ubiquitin-free routes into the proteasome. Cell Mol Life Sci. 2004, 61, 1596-1600
35. Kong, X.; Alvarez-Castelao, B.; Lin, Z.; Castano, J. G.; Caro, J. Constitutive/hypoxic degradation of HIF-alpha proteins by the proteasome is independent of von Hippel Lindau protein ubiquitylation and the transactivation activity of the protein. J. Biol. Chem. 2007, 282, 15498-15505
36. Chen, W.; Lee, J.; Cho, S. Y.; Fine, H. A. Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo. Cancer Res. 2004, 64, 3949-3957
37. Diehl, J. A.; Zindy, F.; Sherr, C. J. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 1997, 11, 957-972
38. Won, K. A.; Reed, S. I. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J. 1996, 15, 4182-4193
39. Blagosklonny, M. V. P53: an ubiquitous target of anticancer drugs. Int. J. Cancer. 2002, 98, 161-166
40. Kalejta, R. F.; Shenk, T. Proteasome-dependent, ubiquitin- independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein. Proc. Natl. Acad. Sci. USA 2003, 100, 3263-3268
41. Li, B.; Dou, Q. P. Bax degradation by the ubiquitin/proteasomedependent pathway: involvement in tumor survival and progression. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 3850-3855
42. Pagano, M.; Tam, S. W.; Theodoras, A. M.; Beer-Romero, P.; Del Sal, G.; Chau, V.; Yew, P. R.; Draetta, G. F.; Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269, 682-685
43. Chen, Z. J. Ubiquitin signalling in the NF-kappaB pathway. Nat. Cell Biol. 2005, 7, 758-765
44. Loda, M.; Cukor, B.; Tam, S. W.; Lavin, P.; Fiorentino, M.; Draetta, G. F.; Jessup, J. M.; Pagano, M. Increased proteasome- dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 1997, 3, 231-234
45. Kumatori, A.; Tanaka, K.; Inamura, N.; Sone, S.; Ogura, T.; Matsumoto, T.; Tachikawa, T.; Shin, S.; Ichihara, A. Abnormally high expression of proteasomes in human leukemic cells. Proc. Natl. Acad. Sci. U. S. A. 1990, 87, 7071-7075
46. Dou, Q. P.; Li, B. Proteasome inhibitors as potential novel anticancer agents. Drug Resist. Updat. 1999, 2, 215-223
47. Almond, J. B.; Cohen, G. M. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002, 16, 433-443
48. Sun, J.; Nam, S.; Lee, C. S.; Li, B.; Coppola, D.; Hamilton, A. D.; Dou, Q. P.; Sebti, S. M. CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Res. 2001, 61, 1280-1284
49. Yang, H.; Chen, D.; Cui, Q. C.; Yuan, X.; Dou, Q. P. Celastrol, a triterpene extracted from the Chinese Thunder of God Vine, is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 2006, 66, 4758-4765
50. Orlowski, R. Z. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ. 1999, 6, 303-313
51. Wojcik, C. Proteasomes in apoptosis: villains or guardians? Cell Mol. Life Sci. 1999, 56, 908-917
52. Frankel, A.; Man, S.; Elliott, P.; Adams, J.; Kerbel, R. S. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin. Cancer Res. 2000, 6, 3719-3728
53. Hideshima, T.; Richardson, P.; Chauhan, D.; Palombella, V. J.; Elliott, P. J.; Adams, J.; Anderson, K. C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001, 61, 3071-3076
54. Schwartz, R.; Davidson, T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park). 2004, 18, 14-21
55. Suh, K. S.; Goy, A. Bortezomib in mantle cell lymphoma. Future Oncol. 2008, 4, 149-168
56. Montagut, C.; Rovira, A.; Albanell, J. The proteasome: a novel target for anticancer therapy. Clin. Transl. Oncol. 2006, 8, 313-317
57. Utecht, K. N.; Kolesar, J. Bortezomib: a novel chemotherapeutic agent for hematologic malignancies. Am. J. Health Syst. Pharm. 2008, 65, 1221-1231
58. Aghajanian, C.; Soignet, S.; Dizon, D. S.; Pien, C. S.; Adams, J.; Elliott, P. J.; Sabbatini, P.; Miller, V.; Hensley, M. L.; Pezzulli, S.; Canales, C.; Daud, A.; Spriggs, D. R. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 2002, 8, 2505-2511
59. Hamilton, A. L.; Eder, J. P.; Pavlick, A. C.; Clark, J. W.; Liebes, L.; Garcia-Carbonero, R.; Chachoua, A.; Ryan, D. P.; Soma, V.; Farrell, K.; Kinchla, N.; Boyden, J.; Yee, H.; Zeleniuch-Jacquotte, A.; Wright, J.; Elliott, P.; Adams, J.; Muggia, F. M. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J. Clin. Oncol. 2005, 23, 6107-6116
60. Crawford, L. J.; Walker, B.; Ovaa, H.; Chauhan, D.; Anderson, K. C.; Morris, T. C.; Irvine, A. E. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res. 2006, 66, 6379-6386
61. Chen, D.; Dou, Q. P. The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention. Curr. Protein Pept. Sci. 2010, 11, 459-470
62. Engel, R. H.; Brown, J. A.; Von Roenn, J. H.; O'Regan, R. M.; Bergan, R.; Badve, S.; Rademaker, A.; Gradishar, W. J. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest. 2007, 25, 733-737
63. Yang, C. H.; Gonzalez-Angulo, A. M.; Reuben, J. M.; Booser, D. J.; Pusztai, L.; Krishnamurthy, S.; Esseltine, D.; Stec, J.; Broglio, K. R.; Islam, R.; Hortobagyi, G. N.; Cristofanilli, M. Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann. Oncol. 2006, 17, 813-817
64. Edelman, M. J. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer. Clin. Lung Cancer 2005, 7 Suppl 2, S64-66
65. Russo, S. M.; Tepper, J. E.; Baldwin, A. S., Jr.; Liu, R.; Adams, J.; Elliott, P.; Cusack, J. C., Jr. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int. J. Radiat. Oncol. Biol. Phys. 2001, 50, 183-193
66. Messersmith, W. A.; Baker, S. D.; Lassiter, L.; Sullivan, R. A.; Dinh, K.; Almuete, V. I.; Wright, J. J.; Donehower, R. C.; Carducci, M. A.; Armstrong, D. K. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin. Cancer Res. 2006, 12, 1270-1275
67. Orlowski, R. Z.; Voorhees, P. M.; Garcia, R. A.; Hall, M. D.; Kudrik, F. J.; Allred, T.; Johri, A. R.; Jones, P. E.; Ivanova, A.; Van Deventer, H. W.; Gabriel, D. A.; Shea, T. C.; Mitchell, B. S.; Adams, J.; Esseltine, D. L.; Trehu, E. G.; Green, M.; Lehman, M. J.; Natoli, S.; Collins, J. M.; Lindley, C. M.; Dees, E. C. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005, 105, 3058-3065
68. Perrone, G.; Hideshima, T.; Ikeda, H.; Okawa, Y.; Calabrese, E.; Gorgun, G.; Santo, L.; Cirstea, D.; Raje, N.; Chauhan, D.; Baccarani, M.; Cavo, M.; Anderson, K. C. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 2009, 23, 1679-1686
69. Ryan, D. P.; O'Neil, B. H.; Supko, J. G.; Rocha Lima, C. M.; Dees, E. C.; Appleman, L. J.; Clark, J.; Fidias, P.; Orlowski, R. Z.; Kashala, O.; Eder, J. P.; Cusack, J. C., Jr. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 2006, 107, 2688-2697
70. Karin, M.; Yamamoto, Y.; Wang, Q. M. The IKK NF-kappa B system: a treasure trove for drug development. Nat. Rev. Drug Discov. 2004, 3, 17-26
71. Chauhan, D.; Anderson, K. C. Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications. Apoptosis 2003, 8, 337-343
72. Ma, M. H.; Yang, H. H.; Parker, K.; Manyak, S.; Friedman, J. M.; Altamirano, C.; Wu, Z. Q.; Borad, M. J.; Frantzen, M.; Roussos, E.; Neeser, J.; Mikail, A.; Adams, J.; Sjak-Shie, N.; Vescio, R. A.; Berenson, J. R. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 2003, 9, 1136-1144
73. Feinman, R.; Koury, J.; Thames, M.; Barlogie, B.; Epstein, J.; Siegel, D. S. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999, 93, 3044-3052
74. Hideshima, T.; Ikeda, H.; Chauhan, D.; Okawa, Y.; Raje, N.; Podar, K.; Mitsiades, C.; Munshi, N. C.; Richardson, P. G.; Carrasco, R. D.; Anderson, K. C. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009, 114, 1046-1052
75. Qin, J. Z.; Ziffra, J.; Stennett, L.; Bodner, B.; Bonish, B. K.; Chaturvedi, V.; Bennett, F.; Pollock, P. M.; Trent, J. M.; Hendrix, M. J.; Rizzo, P.; Miele, L.; Nickoloff, B. J. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 2005, 65, 6282-6293
76. Oda, E.; Ohki, R.; Murasawa, H.; Nemoto, J.; Shibue, T.; Yamashita, T.; Tokino, T.; Taniguchi, T.; Tanaka, N. Noxa, a BH3- only member of the Bcl-2 family and candidate mediator of p53- induced apoptosis. Science 2000, 288, 1053-1058
77. Adams, J. M.; Cory, S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281, 1322-1326
78. Gross, A.; McDonnell, J. M.; Korsmeyer, S. J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999, 13, 1899-1911
79. Nikiforov, M. A.; Riblett, M.; Tang, W. H.; Gratchouck, V.; Zhuang, D.; Fernandez, Y.; Verhaegen, M.; Varambally, S.; Chinnaiyan, A. M.; Jakubowiak, A. J.; Soengas, M. S. Tumor cell- selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 19488-19493
80. Adams, J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 2004, 5, 417-421
81. Caravita, T.; de Fabritiis, P.; Palumbo, A.; Amadori, S.; Boccadoro, M. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nat. Clin. Pract. Oncol. 2006, 3, 374-387
82. Fernandez, Y.; Verhaegen, M.; Miller, T. P.; Rush, J. L.; Steiner, P.; Opipari, A. W., Jr.; Lowe, S. W.; Soengas, M. S. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res. 2005, 65, 6294-6304
83. Qin, J. Z.; Xin, H.; Sitailo, L. A.; Denning, M. F.; Nickoloff, B. J. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res. 2006, 66, 9636-9645
84. Adams, J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr. Opin. Chem. Biol. 2002, 6, 493-500
85. Jagannath, S.; Durie, B. G.; Wolf, J.; Camacho, E.; Irwin, D.; Lutzky, J.; McKinley, M.; Gabayan, E.; Mazumder, A.; Schenkein, D.; Crowley, J. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br. J. Haematol. 2005, 129, 776-783
86. Kondagunta, G. V.; Drucker, B.; Schwartz, L.; Bacik, J.; Marion, S.; Russo, P.; Mazumdar, M.; Motzer, R. J. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J. Clin. Oncol. 2004, 22, 3720-3725
87. Richardson, P. G.; Sonneveld, P.; Schuster, M. W.; Irwin, D.; Stadtmauer, E. A.; Facon, T.; Harousseau, J. L.; Ben-Yehuda, D.; Lonial, S.; Goldschmidt, H.; Reece, D.; San-Miguel, J. F.; Blade, J.; Boccadoro, M.; Cavenagh, J.; Dalton, W. S.; Boral, A. L.; Esseltine, D. L.; Porter, J. B.; Schenkein, D.; Anderson, K. C. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 2005, 352, 2487-2498
88. Shah, S. A.; Potter, M. W.; McDade, T. P.; Ricciardi, R.; Perugini, R. A.; Elliott, P. J.; Adams, J.; Callery, M. P. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell Biochem. 2001, 82, 110-122
89. Sunwoo, J. B.; Chen, Z.; Dong, G.; Yeh, N.; Crowl Bancroft, C.; Sausville, E.; Adams, J.; Elliott, P.; Van Waes, C. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor- kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 2001, 7, 1419-1428
90. Berenson, J. R.; Ma, H. M.; Vescio, R. The role of nuclear factor- kappaB in the biology and treatment of multiple myeloma. Semin. Oncol. 2001, 28, 626-633
91. LeBlanc, R.; Catley, L. P.; Hideshima, T.; Lentzsch, S.; Mitsiades, C. S.; Mitsiades, N.; Neuberg, D.; Goloubeva, O.; Pien, C. S.; Adams, J.; Gupta, D.; Richardson, P. G.; Munshi, N. C.; Anderson, K. C. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002, 62, 4996-5000
92. Nawrocki, S. T.; Bruns, C. J.; Harbison, M. T.; Bold, R. J.; Gotsch, B. S.; Abbruzzese, J. L.; Elliott, P.; Adams, J.; McConkey, D. J. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol. Cancer Ther. 2002, 1, 1243-1253
93. Kukreja, A.; Hutchinson, A.; Mazumder, A.; Vesole, D.; Angitapalli, R.; Jagannath, S.; O'Connor O. A.; Dhodapkar, M. V. Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications. Br. J. Haematol. 2007, 136, 106-110
94. Mitsiades, N.; Mitsiades, C. S.; Poulaki, V.; Chauhan, D.; Fanourakis, G.; Gu, X.; Bailey, C.; Joseph, M.; Libermann, T. A.; Treon, S. P.; Munshi, N. C.; Richardson, P. G.; Hideshima, T.; Anderson, K. C. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 14374-14379
95. Strauss, S. J.; Higginbottom, K.; Juliger, S.; Maharaj, L.; Allen, P.; Schenkein, D.; Lister, T. A.; Joel, S. P. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res. 2007, 67, 2783-2790
96. Fribley, A.; Wang, C. Y. Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol. Ther. 2006, 5, 745-748
97. Fribley, A.; Zeng, Q.; Wang, C. Y. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol. Cell Biol. 2004, 24, 9695-9704
98. Lioni, M.; Noma, K.; Snyder, A.; Klein-Szanto, A.; Diehl, J. A.; Rustgi, A. K.; Herlyn, M.; Smalley, K. S. Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Mol. Cancer Ther. 2008, 7, 2866-2875
99. Markovic, S. N.; Geyer, S. M.; Dawkins, F.; Sharfman, W.; Albertini, M.; Maples, W.; Fracasso, P. M.; Fitch, T.; Lorusso, P.; Adjei, A. A.; Erlichman, C. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 2005, 103, 2584-2589
100. Voortman, J.; Smit, E. F.; Honeywell, R.; Kuenen, B. C.; Peters, G. J.; van de Velde, H.; Giaccone, G. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin. Cancer Res. 2007, 13, 3642-3651
101. Dreicer, R.; Petrylak, D.; Agus, D.; Webb, I.; Roth, B. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin. Cancer Res. 2007, 13, 1208-1215
102. Hainsworth, J. D.; Meluch, A. A.; Spigel, D. R.; Barton, J., Jr.; Simons, L.; Meng, C.; Gould, B.; Greco, F. A. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone- refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial. Clin. Genitourin. Cancer 2007, 5, 278-283
103. Morris, M. J.; Kelly, W. K.; Slovin, S.; Ryan, C.; Eicher, C.; Heller, G.; Scher, H. I. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. J. Urol. 2007, 178, 2378-2383; discussion 2383-2374
104. Richardson, P. G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S. V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Siegel, D.; Orlowski, R. Z.; Kuter, D.; Limentani, S. A.; Lee, S.; Hideshima, T.; Esseltine, D. L.; Kauffman, M.; Adams, J.; Schenkein, D. P.; Anderson, K. C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348, 2609-2617
105. Jagannath, S.; Barlogie, B.; Berenson, J.; Siegel, D.; Irwin, D.; Richardson, P. G.; Niesvizky, R.; Alexanian, R.; Limentani, S. A.; Alsina, M.; Adams, J.; Kauffman, M.; Esseltine, D. L.; Schenkein, D. P.; Anderson, K. C. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. Haematol. 2004, 127, 165-172
106. Oakervee, H. E.; Popat, R.; Curry, N.; Smith, P.; Morris, C.; Drake, M.; Agrawal, S.; Stec, J.; Schenkein, D.; Esseltine, D. L.; Cavenagh, J. D. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br. J. Haematol. 2005, 129, 755-762
107. Belch, A.; Kouroukis, C. T.; Crump, M.; Sehn, L.; Gascoyne, R. D.; Klasa, R.; Powers, J.; Wright, J.; Eisenhauer, E. A. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann. Oncol. 2007, 18, 116-121
108. O'Connor, O. A.; Wright, J.; Moskowitz, C.; Muzzy, J.; MacGregor-Cortelli, B.; Stubblefield, M.; Straus, D.; Portlock, C.; Hamlin, P.; Choi, E.; Dumetrescu, O.; Esseltine, D.; Trehu, E.; Adams, J.; Schenkein, D.; Zelenetz, A. D. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J. Clin. Oncol. 2005, 23, 676-684
109. Scagliotti, G. V.; Germonpre, P.; Bosquee, L.; Vansteenkiste, J.; Gervais, R.; Planchard, D.; Reck, M.; De Marinis, F.; Lee, J. S.; Park, K.; Biesma, B.; Gans, S.; Ramlau, R.; Szczesna, A.; Makhson, A.; Manikhas, G.; Morgan, B.; Zhu, Y.; Chan, K. C.; von Pawel, J. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 2010, 68, 420-426
110. Richardson, P. G.; Sonneveld, P.; Schuster, M. W.; Stadtmauer, E. A.; Facon, T.; Harousseau, J. L.; Ben-Yehuda, D.; Lonial, S.; Goldschmidt, H.; Reece, D.; Blade, J.; Boccadoro, M.; Cavenagh, J. D.; Boral, A. L.; Esseltine, D. L.; Wen, P. Y.; Amato, A. A.; Anderson, K. C.; San Miguel, J. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br. J. Haematol. 2009, 144, 895-903
111. Mikhael, J. R.; Belch, A. R.; Prince, H. M.; Lucio, M. N.; Maiolino, A.; Corso, A.; Petrucci, M. T.; Musto, P.; Komarnicki, M.; Stewart, A. K. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br. J. Haematol. 2009, 144, 169-175
112. Fonseca, R.; Rajkumar, S. V. Consolidation therapy with bortezomib/lenalidomide/dexamethasone versus bortezomib/dexa- methasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial. Clin. Lymphoma Myeloma 2008, 8, 315-317
113. San Miguel, J. F.; Schlag, R.; Khuageva, N. K.; Dimopoulos, M. A.; Shpilberg, O.; Kropff, M.; Spicka, I.; Petrucci, M. T.; Palumbo, A.; Samoilova, O. S.; Dmoszynska, A.; Abdulkadyrov, K. M.; Schots, R.; Jiang, B.; Mateos, M. V.; Anderson, K. C.; Esseltine, D. L.; Liu, K.; Cakana, A.; van de Velde, H.; Richardson, P. G. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 2008, 359, 906-917
114. Mateos, M. V.; Richardson, P. G.; Schlag, R.; Khuageva, N. K.; Dimopoulos, M. A.; Shpilberg, O.; Kropff, M.; Spicka, I.; Petrucci, M. T.; Palumbo, A.; Samoilova, O. S.; Dmoszynska, A.; Abdulkadyrov, K. M.; Schots, R.; Jiang, B.; Esseltine, D. L.; Liu, K.; Cakana, A.; van de Velde, H.; San Miguel, J. F. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J. Clin. Oncol. 2010, 28, 2259-2266
115. Orlowski, R. Z. The ubiquitin proteasome pathway from bench to bedside. Hematology Am. Soc. Hematol. Educ. Program 2005, 220-225
116. Arlt, A.; Bauer, I.; Schafmayer, C.; Tepel, J.; Muerkoster, S. S.; Brosch, M.; Roder, C.; Kalthoff, H.; Hampe, J.; Moyer, M. P.; Folsch, U. R.; Schafer, H. Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene 2009, 28, 3983-3996
117. Ma, W.; Kantarjian, H.; Bekele, B.; Donahue, A. C.; Zhang, X.; Zhang, Z. J.; O'Brien, S.; Estey, E.; Estrov, Z.; Cortes, J.; Keating, M.; Giles, F.; Albitar, M. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin. Cancer Res. 2009, 15, 3820-3826
118. Bazzaro, M.; Lee, M. K.; Zoso, A.; Stirling, W. L.; Santillan, A.; Shih Ie, M.; Roden, R. B. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res. 2006, 66, 3754-3763
119. Chen, D.; Cui, Q. C.; Yang, H.; Dou, Q. P. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 2006, 66, 10425-10433
120. Chen, D.; Daniel, K. G.; Chen, M. S.; Kuhn, D. J.; Landis-Piwowar, K. R.; Dou, Q. P. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem. Pharmacol. 2005, 69, 1421-1432
121. Ovaa, H.; Kessler, B. M.; Rolen, U.; Galardy, P. J.; Ploegh, H. L.; Masucci, M. G. Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 2253-2258
122. Soligo, D.; Servida, F.; Delia, D.; Fontanella, E.; Lamorte, G.; Caneva, L.; Fumiatti, R.; Lambertenghi Deliliers, G. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br. J. Haematol. 2001, 113, 126-135
123. Anderson, K. C.; Kyle, R. A.; Dalton, W. S.; Landowski, T.; Shain, K.; Jove, R.; Hazlehurst, L.; Berenson, J. Multiple Myeloma: New Insights and Therapeutic Approaches. Hematology Am. Soc. Hematol. Educ. Program 2000, 147-165
124. Richardson, P. G.; Hideshima, T.; Anderson, K. C. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003, 10, 361-369
125. Landis-Piwowar, K. R.; Milacic, V.; Chen, D.; Yang, H.; Zhao, Y.; Chan, T. H.; Yan, B.; Dou, Q. P. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist. Updat. 2006, 9, 263-273
126. Goktas, S.; Baran, Y.; Ural, A. U.; Yazici, S.; Aydur, E.; Basal, S.; Avcu, F.; Pekel, A.; Dirican, B.; Beyzadeoglu, M. Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells. Urology 2010, 75, 793-798
127. Pervan, M.; Pajonk, F.; Sun, J. R.; Withers, H. R.; McBride, W. H. Molecular pathways that modify tumor radiation response. Am. J. Clin. Oncol. 2001, 24, 481-485
128. Curran, M. P.; McKeage, K. Bortezomib: a review of its use in patients with multiple myeloma. Drugs 2009, 69, 859-888
129. Pei, X. Y.; Dai, Y.; Grant, S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin. Cancer Res. 2004, 10, 3839-3852
130. Landowski, T. H.; Megli, C. J.; Nullmeyer, K. D.; Lynch, R. M.; Dorr, R. T. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res. 2005, 65, 3828-3836
131. Goy, A.; Younes, A.; McLaughlin, P.; Pro, B.; Romaguera, J. E.; Hagemeister, F.; Fayad, L.; Dang, N. H.; Samaniego, F.; Wang, M.; Broglio, K.; Samuels, B.; Gilles, F.; Sarris, A. H.; Hart, S.; Trehu, E.; Schenkein, D.; Cabanillas, F.; Rodriguez, A. M. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 2005, 23, 667-675
132. Lu, S.; Chen, Z.; Yang, J.; Chen, L.; Gong, S.; Zhou, H.; Guo, L.; Wang, J. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Exp. Hematol. 2008, 36, 1278-1284
133. Lu, S.; Yang, J.; Chen, Z.; Gong, S.; Zhou, H.; Xu, X.; Wang, J. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line. Exp. Hematol. 2009, 37, 831-837
134. Lu, S.; Yang, J.; Song, X.; Gong, S.; Zhou, H.; Guo, L.; Song, N.; Bao, X.; Chen, P.; Wang, J. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J. Pharmacol. Exp. Ther. 2008, 326, 423-431
135. Oerlemans, R.; Franke, N. E.; Assaraf, Y. G.; Cloos, J.; van Zantwijk, I.; Berkers, C. R.; Scheffer, G. L.; Debipersad, K.; Vojtekova, K.; Lemos, C.; van der Heijden, J. W.; Ylstra, B.; Peters, G. J.; Kaspers, G. L.; Dijkmans, B. A.; Scheper, R. J.; Jansen, G. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008, 112, 2489-2499
136. Golden, E. B.; Lam, P. Y.; Kardosh, A.; Gaffney, K. J.; Cadenas, E.; Louie, S. G.; Petasis, N. A.; Chen, T. C.; Schonthal, A. H. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009, 113, 5927-5937
137. Kim, T. Y.; Park, J.; Oh, B.; Min, H. J.; Jeong, T. S.; Lee, J. H.; Suh, C.; Cheong, J. W.; Kim, H. J.; Yoon, S. S.; Park, S. B.; Lee, D. S. Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction. Br. J. Haematol. 2009, 146, 270-281
138. Liu, F. T.; Agrawal, S. G.; Movasaghi, Z.; Wyatt, P. B.; Rehman, I. U.; Gribben, J. G.; Newland, A. C.; Jia, L. Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood 2008, 112, 3835-3846
139. Shah, M. H.; Young, D.; Kindler, H. L.; Webb, I.; Kleiber, B.; Wright, J.; Grever, M. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 2004, 10, 6111-6118
140. Yang, H.; Zonder, J. A.; Dou, Q. P. Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin. Investig. Drugs 2009, 18, 957-971
141. Orlowski, R. Z.; Nagler, A.; Sonneveld, P.; Blade, J.; Hajek, R.; Spencer, A.; San Miguel, J.; Robak, T.; Dmoszynska, A.; Horvath, N.; Spicka, I.; Sutherland, H. J.; Suvorov, A. N.; Zhuang, S. H.; Parekh, T.; Xiu, L.; Yuan, Z.; Rackoff, W.; Harousseau, J. L. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J. Clin. Oncol. 2007, 25, 3892-3901
142. Popat, R.; Oakervee, H.; Williams, C.; Cook, M.; Craddock, C.; Basu, S.; Singer, C.; Harding, S.; Foot, N.; Hallam, S.; Odeh, L.; Joel, S.; Cavenagh, J. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br. J. Haematol. 2009, 144, 887-894
143. Reece, D. E.; Rodriguez, G. P.; Chen, C.; Trudel, S.; Kukreti, V.; Mikhael, J.; Pantoja, M.; Xu, W.; Stewart, A. K. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J. Clin. Oncol. 2008, 26, 4777-4783
144. Terpos, E.; Kastritis, E.; Roussou, M.; Heath, D.; Christoulas, D.; Anagnostopoulos, N.; Eleftherakis-Papaiakovou, E.; Tsionos, K.; Croucher, P.; Dimopoulos, M. A. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008, 22, 2247-2256
145. Berenson, J. R.; Matous, J.; Swift, R. A.; Mapes, R.; Morrison, B.; Yeh, H. S. A phase I/II study of arsenic trioxide/bortezomib/ ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin. Cancer Res. 2007, 13, 1762-1768
146. Fanucchi, M. P.; Fossella, F. V.; Belt, R.; Natale, R.; Fidias, P.; Carbone, D. P.; Govindan, R.; Raez, L. E.; Robert, F.; Ribeiro, M.; Akerley, W.; Kelly, K.; Limentani, S. A.; Crawford, J.; Reimers, H. J.; Axelrod, R.; Kashala, O.; Sheng, S.; Schiller, J. H. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 2006, 24, 5025-5033
147. Bhatnagar, I.; Kim, S. K. Marine antitumor drugs: status, shortfalls and strategies. Mar. Drugs 2010, 8, 2702-2720
148. Chauhan, D.; Hideshima, T.; Anderson, K. C. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br. J. Cancer 2006, 95, 961-965
149. Chen, D.; Milacic, V.; Chen, M. S.; Wan, S. B.; Lam, W. H.; Huo, C.; Landis-Piwowar, K. R.; Cui, Q. C.; Wali, A.; Chan, T. H.; Dou, Q. P. Tea polyphenols, their biological effects and potential molecular targets. Histol. Histopathol. 2008, 23, 487-496
150. Nam, S.; Smith, D. M.; Dou, Q. P. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J. Biol. Chem. 2001, 276, 13322-13330
151. Kazi, A.; Daniel, K. G.; Smith, D. M.; Kumar, N. B.; Dou, Q. P. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem. Pharmacol. 2003, 66, 965-976
152. Jana, N. R.; Dikshit, P.; Goswami, A.; Nukina, N. Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J. Biol. Chem. 2004, 279, 11680-11685
153. Milacic, V.; Banerjee, S.; Landis-Piwowar, K. R.; Sarkar, F. H.; Majumdar, A. P.; Dou, Q. P. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res. 2008, 68, 7283-7292
154. Chen, D.; Landis-Piwowar, K. R.; Chen, M. S.; Dou, Q. P. Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts. Breast Cancer Res. 2007, 9, R80
155. Ali, S.; Ahmad, A.; Banerjee, S.; Padhye, S.; Dominiak, K.; Schaffert, J. M.; Wang, Z.; Philip, P. A.; Sarkar, F. H. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 2010, 70, 3606-3617
156. Landis-Piwowar, K. R.; Huo, C.; Chen, D.; Milacic, V.; Shi, G.; Chan, T. H.; Dou, Q. P. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res. 2007, 67, 4303-4310
157. Padhye, S.; Banerjee, S.; Chavan, D.; Pandye, S.; Swamy, K. V.; Ali, S.; Li, J.; Dou, Q. P.; Sarkar, F. H. Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm. Res. 2009, 26, 2438-2445
158. Padhye, S.; Yang, H.; Jamadar, A.; Cui, Q. C.; Chavan, D.; Dominiak, K.; McKinney, J.; Banerjee, S.; Dou, Q. P.; Sarkar, F. H. New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm. Res. 2009, 26, 1874-1880
159. Yang, H.; Sun, D. K.; Chen, D.; Cui, Q. C.; Gu, Y. Y.; Jiang, T.; Chen, W.; Wan, S. B.; Dou, Q. P. Antitumor activity of novel fluoro-substituted (-)-epigallocatechin-3-gallate analogs. Cancer Lett. 2010, 292, 48-53
160. Pray, T. R.; Parlati, F.; Huang, J.; Wong, B. R.; Payan, D. G.; Bennett, M. K.; Issakani, S. D.; Molineaux, S.; Demo, S. D. Cell cycle regulatory E3 ubiquitin ligases as anticancer targets. Drug Resist. Updat. 2002, 5, 249-258
161. Jia, L.; Yang, J.; Hao, X.; Zheng, M.; He, H.; Xiong, X.; Xu, L.; Sun, Y. Validation of SAG/RBX2/ROC2 E3 ubiquitin ligase as an anticancer and radiosensitizing target. Clin. Cancer Res. 2010, 16, 814-824
162. Honda, R.; Tanaka, H.; Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997, 420, 25-27
163. Soucy, T. A.; Smith, P. G.; Milhollen, M. A.; Berger, A. J.; Gavin, J. M.; Adhikari, S.; Brownell, J. E.; Burke, K. E.; Cardin, D. P.; Critchley, S.; Cullis, C. A.; Doucette, A.; Garnsey, J. J.; Gaulin, J. L.; Gershman, R. E.; Lublinsky, A. R.; McDonald, A.; Mizutani, H.; Narayanan, U.; Olhava, E. J.; Peluso, S.; Rezaei, M.; Sintchak, M. D.; Talreja, T.; Thomas, M. P.; Traore, T.; Vyskocil, S.; Weatherhead, G. S.; Yu, J.; Zhang, J.; Dick, L. R.; Claiborne, C. F.; Rolfe, M.; Bolen, J. B.; Langston, S. P. An inhibitor of NEDD8- activating enzyme as a new approach to treat cancer. Nature 2009, 458, 732-736